Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has met with the U.S. Food and Drug Administration (FDA) to discuss the matters raised in the Agency's May 30, 2007 Approvable Letter for the Company's once-daily formulation of tramadol. The Company believes that the meeting with the Agency was productive and that the statistical analysis required by the FDA to achieve approval has been clearly delineated. If the existing data cannot satisfy these statistical requirements, the Company would be required to generate new data through an additional Phase III clinical trial. Labopharm will provide additional updates as it continues to interact with the FDA, as well as work with its marketing partner for the U.S., Purdue Pharma, and its advisors.